A path toward clinical trial diversity

Minority and marginalized communities have historically been underrepresented in local and federal governments and in dozens of private sectors globally. Pharma is no different; there exists a steep chasm that drugmakers have yet to bridge concerning research and trials. The longer this gulf exists, the harder it becomes to address – the feelings of mistrust, Read more… A path toward clinical trial diversity originally appeared in KevinMD.com.

Read the full post at KevinMD.com
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive